💥小细胞 #lungcancer 的颠覆性突破！#ESMO26 LBA3 DeLLphi-305：Tarlatamab + durvalumab 对比 durvalumab 1L 维持治疗，用于化疗-免疫治疗后的 ES-SCLC（n=563）。中位 OS ⬆️21.1 vs 12.7 个月（HR 0.42），PFS ⬆️7.4 vs 1.9 个月（HR 0.34），ORR 26% vs 4%。☢️44% 的患者仍使用 T+D，原因是针对寡进展病灶进行了 #radiotherapy？ #SCLC #LCSM @NEJM ➡️ https://shorturl.at/IiOO1
204 浏览 · 7 赞 · 2 转发 · 1 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org- Mark Storey@ProtonStorey
@_ShankarSiva @sands_jacob @bensolomon1 @jryckman3 @DrJNaidoo @StephenVLiu @NarjustFlorezMD @peters_solange @tnewsomdavis @DrRiyazShah @bslotman Based on curves and censor marks, I bet it strengthens with longer followup. I think the means might understate the impact. Impressive progress for this cohort
来源：Shankar Siva · x.com